Childhood influenza
Conditions
Interventions
Control group:Oseltamivir phosphate granule and Xiaoer Feireqing granule simulator
Experimental group:Xiaoer Feireqing granule and oseltamivir phosphate granule simulator
Sponsors
The First Affiliated Hospital of Tianjin University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
1 Years to 14 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria (1) meet the Western medicine diagnostic criteria for childhood influenza; (2) Conforming to the syndrome differentiation standard of TCM heat toxicity attacking lung; (3) nasopharyngeal/oropharyngeal swab influenza virus rapid antigen test positive; (4) At least one single symptom of CARIFs symptom dimension was moderate or above at the time of enrollment; (5) Age 1-14 years old (< 15 years old); (6) The duration from fever to treatment was less than 72h and the maximum axillary temperature was =38.0? 24h before diagnosis; (7) The informed consent process should be in accordance with the regulations and the legal guardian or the subject child (=8 years old) should sign the informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria (1) Severe or critical influenza cases; (2) Patients with pharyngeal conjunctiva fever herpetic angina suppurative tonsillitis and other respiratory tract infections; (3) Influenza complications including but not limited to sinusitis otitis media pneumonia myocarditis encephalitis encephalopathy and other influenza complications (except bronchitis); (4) Antiviral drugs (chemicals including oseltamivir zanamivir and peramivir etc.) had been used within 72 hours prior to this visit; Traditional Chinese medicine includes Lianhua Qingwen capsule cold Qingre granule Jinhua Qinggan granule etc.); (5) is systematically receiving steroid therapy or other immunosuppressive therapy; (6) A history of epilepsy or febrile convulsions repeated respiratory infections; (7) chronic respiratory heart kidney liver blood endocrine nervous system and immune deficiencies and other underlying diseases; (8) glucose-6-phosphate dehydrogenase deficiency (broad bean disease); (9) Allergic to known components of the investigational drug product; (10) Participants considered inappropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical recovery time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete regression time;Incidence of complications/severe/critical influenza;Variation value/effective rate of TCM syndrome score;Disappearance rate of single symptom;Virus negative conversion rate;CARIFS symptom score change;Acetaminophen use; | — |
Countries
China
Contacts
Public ContactRong Ping
The First Affiliated Hospital of Tianjin University of Chinese Medicine
Outcome results
None listed